Aeroallergy Research Laboratory — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$48,044	6
2024	Research	$77,592	3
2023	Research	$42,183	6
2022	Research	$7,812	4
2021	Research	$64,377	5
2020	Research	$24,569	7

Breakdown

Who paid Research payments · program years 2020–2025

Novartis Pharmaceuticals Corporation $159,283 11 payments
Celgene Corporation $49,621 2 payments
AstraZeneca Pharmaceuticals LP $34,437 13 payments
AstraZeneca AB $13,570 3 payments
E.R. Squibb & Sons, L.L.C. $7,666 2 payments

Studies the money was for Research payments · program years 2020–2025

A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines $83,718 2 payments
A Phase 2, Multicenter, Global, Randomized, Double $44,908 1 payment
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista $29,258 2 payments
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co $17,483 2 payments
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous Urticaria Patients Who Completed the Preceding Remibrutinib Phase 3 Studies $17,388 2 payments
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $14,645 7 payments
A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. $13,570 3 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Remibrutinib (Lou064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (Csu) Patients Inadequately Controlled By H1-Antihistamines $11,085 2 payments
A Multicenter, Randomized, Open-label, Parallel group, Functionality, and Performance Study of an Accessorized Pre-filled Syringe and Autoinjector with Home-administered Tezepelumab in Adolescent and Adult Subjects with Severe Asthma $10,598 2 payments
Phase II Umbrella AD - A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients with Moderate to Severe Atopic Dermatitis $7,666 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.